Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
J Virol. 2014 May;88(9):4624-31. doi: 10.1128/JVI.00005-14. Epub 2014 Feb 12.
Hendra virus (HeV) is a zoonotic emerging virus belonging to the family Paramyxoviridae. HeV causes severe and often fatal respiratory and/or neurologic disease in both animals and humans. Currently, there are no licensed vaccines or antiviral drugs approved for human use. A number of animal models have been developed for studying HeV infection, with the African green monkey (AGM) appearing to most faithfully reproduce the human disease. Here, we assessed the utility of a newly developed recombinant subunit vaccine based on the HeV attachment (G) glycoprotein in the AGM model. Four AGMs were vaccinated with two doses of the HeV vaccine (sGHeV) containing Alhydrogel, four AGMs received the sGHeV with Alhydrogel and CpG, and four control animals did not receive the sGHeV vaccine. Animals were challenged with a high dose of infectious HeV 21 days after the boost vaccination. None of the eight specifically vaccinated animals showed any evidence of clinical illness and survived the challenge. All four controls became severely ill with symptoms consistent with HeV infection, and three of the four animals succumbed 8 days after exposure. Success of the recombinant subunit vaccine in AGMs provides pivotal data in supporting its further preclinical development for potential human use.
A Hendra virus attachment (G) glycoprotein subunit vaccine was tested in nonhuman primates to assess its ability to protect them from a lethal infection with Hendra virus. It was found that all vaccinated African green monkeys were completely protected against subsequent Hendra virus infection and disease. The success of this new subunit vaccine in nonhuman primates provides critical data in support of its further development for future human use.
亨德拉病毒（HeV）是一种人畜共患的新兴病毒，属于副粘病毒科。HeV 可导致动物和人类发生严重且常致命的呼吸道和/或神经系统疾病。目前，尚无获准用于人类的疫苗或抗病毒药物。已经开发了多种动物模型来研究 HeV 感染，其中非洲绿猴（AGM）似乎最能真实再现人类疾病。在这里，我们评估了一种基于 HeV 附着（G）糖蛋白的新型重组亚单位疫苗在 AGM 模型中的应用。四头 AGM 用含有氢氧化铝凝胶的两剂 HeV 疫苗（sGHeV）接种，四头 AGM 用 sGHeV 加氢氧化铝凝胶和 CpG 接种，四头对照动物未接种 sGHeV 疫苗。在加强接种后 21 天，动物接受了高剂量的传染性 HeV 挑战。八只特异性接种的动物中没有一只出现任何临床疾病的迹象，并在挑战中存活下来。所有四只对照动物均出现严重疾病，症状与 HeV 感染一致，其中四只动物中的三只在暴露后 8 天死亡。重组亚单位疫苗在 AGM 中的成功为支持其进一步临床前开发以用于潜在的人类用途提供了关键数据。
一种亨德拉病毒附着（G）糖蛋白亚单位疫苗在非人类灵长类动物中进行了测试，以评估其保护它们免受致命亨德拉病毒感染的能力。结果发现，所有接种的非洲绿猴均完全免受随后的亨德拉病毒感染和疾病的影响。这种新型亚单位疫苗在非人类灵长类动物中的成功为支持其进一步开发用于未来人类用途提供了关键数据。
